True Royalty Television is the first and only established TV channel serving the global millions of Royal super-fans, with 20,000 paying subscribers already on its platform. The British Royal Family is the 4th biggest brand in the world. With 350+ hours of top quality Royal content, refreshed monthly and with exclusive commissions, True Royalty curates relevant titles according to Royal news and the viewer's interest areas—British Royals, World Royals, and Royalty through history. There are 25 million people in the US alone who identify as both active Royal fans and who stream on-demand TV, up almost 300% from 8.6 million in 2018. The founders of the channel have assembled a diverse team of proven experts in TV production and distribution, digital marketing, PR, and brand partnerships from around the world. With the investment, the channel has identified partners for further growth opportunities including launching beyond the current US, Canada, Australia, NZ, UK & Ireland into India, Europe, the Middle East, and the Far East demographics.
days to go:
Expired
investment:
£2,148,699
TV.FIT is a streaming service and app that allows its users to access 100 hours of health & wellbeing content from global fitness experts & celebrities. Its subscription service is accessible in 66 countries across 6 continents. The platform aims to cater to all aspects of fitness, from mental health support for those who have yet to start to improve their fitness to creating content for those who are already working on their fitness regime. Its programs are created by some of the world’s most well-known fitness figures including George St-Pierre, Caroline Pearce, Gemma Atkinson, and Pierre Pozzuto. The platform has a global multimedia reach of over 8 million followers via partners such as TruFusion and CoolEvents, with another 6 million+ prospective users in the pipeline. TV.FIT also disseminates NHS-recommended mental-health-focused content on its platform. With the funds received, the platform aims to invest 31% of it in marketing, 28% in international content development, 22% in capital reserves, 18% in content production, and 1% towards repayment of debt.
days to go:
Expired
investment:
£2,208,212
MysteryVibe creates doctor-recommended sexual health devices. The company combines research and engineering by onboarding leading doctors to design devices that address major sexual health issues such as erectile dysfunction, dryness and pain during intercourse. MysteryVibe has changed over 50,000 lives in 65 countries, witnessed $1 million worth of direct sales in 2020, and became the first sexual health startup to be featured on a BBC documentary. The company has received 20+ international awards including, the coveted Design Week Awards where its product, 'Crescendo', beat the Apple Watch. MysteryVibe has featured in media entities like Men's Health, Women's Health, The Daily Dot, and Forbes, to name a few. The company will use 25% of the investment to expand and scale its digital marketing campaign, 25% to launch two new products, 25% to expand its team, and 25% on building its inventory.
days to go:
Expired
investment:
£498,020
paus is an on-demand streaming service. It offers specialist, hand-picked independent films to today's streamers who wish to avail a niche streaming service in 2020. The company aims to propel curated independent cinema into the $161 billion global streaming market by replacing conventional subscription and ad-based models with a peer-to-peer digital tipping model. paus is working with globally recognised film institutions to procure curated content. Over 1,900 people have signed up for early access to its iOS app. The company is currently rolling out a beta iOS version in the UK and US. It will use the investment to move into streaming theatre and web-series on its portal.
days to go:
Expired
investment:
£352,724
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.
days to go:
Expired
investment:
£70,900
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
Alyve provides personalised subscription nutrition powered by Artificial Intelligence (AI). It argues that 8.2 million UK vitamin users are looking for personalised nutrition in one capsule. Alyve asserts that its product can fulfil this demand. Users complete a 3-minute questionnaire where their responses are recorded by Alyve's intelligent algorithms. These then, based on the responses, help the user select one of Alyve's nutritional pills best matched to their goals and needs. Alyve then delivers the pills to the user's doorstep every 30 days. The company has recorded 4000+ questionnaires and completed 800+ orders in 25 countries since Q4 of 2020. It aims to become a contender in the $21 billion supplement market. The company will use the investment received to increase marketing efforts, transform Alyve into a household brand, introduce new product lines, increase staff, improve technology, and transform both digital and physical User Experiences (UX).
days to go:
Expired
investment:
£227,782
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
